{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:08:06Z","timestamp":1794049686481,"version":"4.8.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.neuropharm.2020.108233","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T12:33:53Z","timestamp":1597408433000},"page":"108233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Targeting the 5-HT system: Potential side effects"],"prefix":"10.1016","volume":"179","author":[{"given":"Daniel","family":"Hoyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108233_bib1","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656560802532707","article-title":"Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders","volume":"9","author":"Abbas","year":"2008","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2020.108233_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/oxfordjournals.schbul.a007102","article-title":"The International Suicide Prevention Trial (InterSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients","volume":"30","author":"Alphs","year":"2004","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2020.108233_bib3","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajhp\/62.7.700","article-title":"Rationale for using serotonergic agents to treat irritable bowel syndrome","volume":"62","author":"Baker","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.neuropharm.2020.108233_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/oby.2004.46","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"12","author":"Barrett","year":"2004","journal-title":"Obes. Res."},{"key":"10.1016\/j.neuropharm.2020.108233_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.vph.2012.11.002","article-title":"An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, velusetrag and TD-8954","volume":"58","author":"Beattie","year":"2013","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib7","first-page":"355","article-title":"The expanded biology of serotonin","volume":"vol. 60","author":"Berger","year":"2009"},{"key":"10.1016\/j.neuropharm.2020.108233_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1185\/03007995.2010.547933","article-title":"Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes","volume":"27","author":"Bleser","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuropharm.2020.108233_bib9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1183\/09031936.00086308","article-title":"Fenfluramine-like cardiovascular side-effects of benfluorex","volume":"33","author":"Boutet","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.neuropharm.2020.108233_bib10","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/jm00013a009","article-title":"The serotonin 5-ht4 receptor .1. Design of a new class of agonists and receptor map of the agonist recognition site","volume":"38","author":"Buchheit","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108233_bib11","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1021\/jm00013a010","article-title":"The serotonin 5-ht4 receptor .2. Structure-activity studies of the indole carbazimidamide class of agonists","volume":"38","author":"Buchheit","year":"1995","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108233_bib12","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108233_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108233_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2001.21908","article-title":"Management of the irritable bowel syndrome","volume":"120","author":"Camilleri","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ajg.2009.20","article-title":"Is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome?","volume":"104","author":"Camilleri","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib16","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/14656566.2013.794223","article-title":"Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome","volume":"14","author":"Camilleri","year":"2013","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2020.108233_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.vascn.2013.12.004","article-title":"Safety Pharmacology assessment of drugs with biased 5-HT2B receptor agonism mediating cardiac valvulopathy","volume":"69","author":"Cavero","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.neuropharm.2020.108233_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2009.07.010","article-title":"Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries","volume":"619","author":"Chan","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ajg.2010.25","article-title":"Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences","volume":"105","author":"Chang","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2982.1999.00148.x","article-title":"The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat","volume":"11","author":"Clayton","year":"1999","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.neuropharm.2020.108233_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/jcbfm.1992.70","article-title":"Effect of sumatriptan, a selective 5-HT(1)-like receptor agonist, on pial vessel diameter in anesthetized cats","volume":"12","author":"Connor","year":"1992","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/heartjnl-2012-302239","article-title":"Drug-induced valvular heart disease","volume":"99","author":"Cosyns","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.neuropharm.2020.108233_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/postgradmedj-2012-302239rep","article-title":"Drug-induced valvular heart disease (Reprinted from Heart, vol 99, pg 7-12, 2013)","volume":"89","author":"Cosyns","year":"2013","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.neuropharm.2020.108233_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2036.2012.05208.x","article-title":"Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS","volume":"36","author":"Cremonini","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108233_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-6-34","article-title":"Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals","volume":"6","author":"Dahl","year":"2008","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2020.108233_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/jnnp.2010.228387","article-title":"Preliminary evidence of hippocampal damage in chronic users of ecstasy","volume":"83","author":"den Hollander","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108233_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038273","article-title":"Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus","volume":"7","author":"Derumeaux","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2020.108233_bib28","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ejechocard\/jeq181","article-title":"Benfluorex: the last chapter of drug-induced valvular heart disease?","volume":"12","author":"Droogmans","year":"2011","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12012-009-9046-2","article-title":"Dose dependency and reversibility of serotonin-induced valvular heart disease in rats","volume":"9","author":"Droogmans","year":"2009","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib31","doi-asserted-by":"crossref","first-page":"H1940","DOI":"10.1152\/ajpheart.01177.2008","article-title":"Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study","volume":"296","author":"Droogmans","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(03)00439-3","article-title":"Convulsive ergotism: epidemics of the serotonin syndrome?","volume":"2","author":"Eadie","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib33","first-page":"348","article-title":"Mitral and aortic valvular disease associated with benfluorex use","volume":"20","author":"Etienne","year":"2011","journal-title":"J. Heart Valve Dis."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108233_bib34","article-title":"Tegaserod for the treatment of irritable bowel syndrome and chronic constipation","author":"Evans","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2020.108233_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ddr.430260304","article-title":"The development of a highly selective 5-ht(1) receptor agonist, sumatriptan, for the treatment of migraine","volume":"26","author":"Feniuk","year":"1992","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2020.108233_bib36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","article-title":"Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials","volume":"22","author":"Ferrari","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2020.108233_bib37","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/0333102410375512","article-title":"Acute treatment of migraine with the selective 5-HTIF receptor agonist lasmiditan - a randomised proof-of-concept trial","volume":"30","author":"Ferrari","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2020.108233_bib38","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.lpm.2011.02.019","article-title":"Benfluorex (Mediator (R)), our vigilance in question","volume":"40","author":"Frachon","year":"2011","journal-title":"Presse Med."},{"key":"10.1016\/j.neuropharm.2020.108233_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010128","article-title":"Benfluorex and unexplained valvular heart disease: a case-control study","volume":"5","author":"Frachon","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2020.108233_bib41","article-title":"Benfluorex and unexplained valvular heart disease: a case- control study","volume":"24","author":"Frachon","year":"2010","journal-title":"Fund. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00001813-199204000-00001","article-title":"Selectivity of 5-HT3 receptor antagonists and antiemetic mechanisms of action","volume":"3","author":"Freeman","year":"1992","journal-title":"Anti Canc. Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108233_bib43","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1038\/s41598-018-26656-2","article-title":"Psilocybin and MDMA reduce costly punishment in the Ultimatum Game","volume":"8","author":"Gabay","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108233_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1476-5381.1957.tb00142.x","article-title":"Two kinds of tryptamine receptor","volume":"12","author":"Gaddum","year":"1957","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"10.1016\/j.neuropharm.2020.108233_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1098-1128(199703)17:2<163::AID-MED2>3.0.CO;2-Y","article-title":"Serotonin 5-HT3 and 5-HT4 receptor antagonists","volume":"17","author":"Gaster","year":"1997","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2020.108233_bib46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","article-title":"The serotonin signaling system: from basic understanding to drug development-for functional GI disorders","volume":"132","author":"Gershon","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2533\/000942906777675164","article-title":"Albert Hofmann's pioneering work on ergot alkaloids and its impact on the search of novel drugs at Sandoz, a predecessor company of Novartis - dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday","volume":"60","author":"Giger","year":"2006","journal-title":"Chimia"},{"key":"10.1016\/j.neuropharm.2020.108233_bib48","first-page":"195","article-title":"Case history on tegaserod (zelnorm (R)\/Zelmac (R))","volume":"vol. 42","author":"Giger","year":"2007"},{"key":"10.1016\/j.neuropharm.2020.108233_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00023210-199810040-00005","article-title":"Serotonin 5-HT1B\/1D receptor agonists in migraine - comparative pharmacology and its therapeutic implications","volume":"10","author":"Goadsby","year":"1998","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2020.108233_bib50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpneuro0639","article-title":"Emerging therapies for migraine","volume":"3","author":"Goadsby","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib51","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1365-2036.2010.04456.x","article-title":"Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study","volume":"32","author":"Goldberg","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108233_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"OPINION the 'atypicality' of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Grunder","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108233_bib53","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1021\/jm100600y","article-title":"Validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs","volume":"53","author":"Hajjo","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108233_bib54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108233_bib55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00002018-200427090-00001","article-title":"Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome","volume":"27","author":"Hasler","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.neuropharm.2020.108233_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/07357900009038248","article-title":"Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting","volume":"18","author":"Hesketh","year":"2000","journal-title":"Canc. Invest."},{"key":"10.1016\/j.neuropharm.2020.108233_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00210-011-0687-x","article-title":"The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations","volume":"385","author":"Higgins","year":"2012","journal-title":"N. Schmied. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib58","article-title":"Discovery of LSD and subsequent investigations of related magic drugs of Mexico","volume":"38","author":"Hofmann","year":"1975","journal-title":"Lloydia-the Journal of Natural Products"},{"key":"10.1016\/j.neuropharm.2020.108233_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000136803","article-title":"Historical view on ergot alkaloids","volume":"16","author":"Hofmann","year":"1978","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","article-title":"How LSD originated","volume":"11","author":"Hofmann","year":"1979","journal-title":"J. Psychedelic Drugs"},{"key":"10.1016\/j.neuropharm.2020.108233_bib61","series-title":"History of the Discovery of LSD","first-page":"7","author":"Hofmann","year":"1994"},{"key":"10.1016\/j.neuropharm.2020.108233_bib62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF01986673","article-title":"Notes and documents concerning the discovery of LSD","volume":"43","author":"Hofmann","year":"1994","journal-title":"Agents Actions"},{"key":"10.1016\/j.neuropharm.2020.108233_bib63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00002826-200603000-00005","article-title":"Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis","volume":"29","author":"Hofmann","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib64","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108233_bib65","first-page":"57","article-title":"Pathological conditions associated with the disturbance of the 5-HT system, in Anti-Targets II","volume":"vol. 66","author":"Hoyer","year":"2015"},{"key":"10.1016\/j.neuropharm.2020.108233_bib66","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102489009S10181","article-title":"A comparison of the interactions of dihydroergotamine, ergotamine and GR 43175 with 5-HT1 receptor subtypes","volume":"9","author":"Hoyer","year":"1989","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2020.108233_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2020.108233_bib68","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","article-title":"Molecular, pharmacological and functional diversity of 5-HT receptors","volume":"71","author":"Hoyer","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108233_bib69","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/mol.109.058057","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment","volume":"76","author":"Huang","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib71","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1526-4610.2008.01097.x","article-title":"The discovery and development of the triptans, a major therapeutic breakthrough","volume":"48","author":"Humphrey","year":"2008","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2020.108233_bib73","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000116755","article-title":"Preclinical studies on the antimigraine drug, sumatriptan","volume":"31","author":"Humphrey","year":"1991","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1749-6632.1990.tb16912.x","article-title":"Serotonin and migraine","volume":"600","author":"Humphrey","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2020.108233_bib75","series-title":"Serotonin, Sumatriptan and Migraine","first-page":"323","author":"Humphrey","year":"1993"},{"key":"10.1016\/j.neuropharm.2020.108233_bib76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1468-2982.1994.1406401.x","article-title":"The mode of action of sumatriptan is vascular - a debate","volume":"14","author":"Humphrey","year":"1994","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2020.108233_bib78","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.25.1_supplement.177.5","article-title":"Antagonism of the 5-HT2B receptor prevents TGF-beta1 effects in aortic valve fibroblasts","volume":"25","author":"Hutcheson","year":"2011","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2020.108233_bib79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease-It was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108233_bib80","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin mechanisms in heart valve disease I - Serotonin-induced up-regulation of transforming growth factor-beta 1 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib81","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0091-3057(01)00745-6","article-title":"The medical benefit of 5-HT research","volume":"71","author":"Jones","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108233_bib82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2710.2002.00426.x","article-title":"A systematic review of tegaserod for the treatment of irritable bowel syndrome","volume":"27","author":"Jones","year":"2002","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108233_bib83","first-page":"62","article-title":"Clozapine in treatment-resistant schizophrenics","volume":"24","author":"Kane","year":"1988","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2020.108233_bib84","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/BF00442561","article-title":"Clozapine for the treatment-resistant schizophrenic - results of a united-states multicenter trial","volume":"99","author":"Kane","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib85","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic - a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib86","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.55.2.294","article-title":"Expedited publication - striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user","volume":"55","author":"Kish","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0269881108097724","article-title":"Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study","volume":"24","author":"Kish","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib88","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/brain\/awq103","article-title":"Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography\/C-11 DASB and structural brain imaging study","volume":"133","author":"Kish","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108233_bib89","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/00952999209026070","article-title":"Chronic 3,4-methylenedioxymethamphetamine (MDMA) use - effects on mood and neuropsychological function","volume":"18","author":"Krystal","year":"1992","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2020.108233_bib90","first-page":"60","article-title":"Clozapine - the atypical antipsychotic - discussion","volume":"160","author":"Kupp","year":"1992","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108233_bib91","doi-asserted-by":"crossref","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib92","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.1121358109","article-title":"Hallucinogen actions on human brain revealed","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108233_bib93","author":"Le Monde"},{"key":"10.1016\/j.neuropharm.2020.108233_bib94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/egh.09.72","article-title":"Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective","volume":"4","author":"Lewis","year":"2010","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib95","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/11590690-000000000-00000","article-title":"The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies","volume":"34","author":"Lewis","year":"2011","journal-title":"Drug Saf."},{"key":"10.1016\/j.neuropharm.2020.108233_bib96","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1468-2982.2003.00690.x","article-title":"Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review","volume":"24","author":"Lipton","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2020.108233_bib97","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1016\/j.bmcl.2012.08.051","article-title":"Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation","volume":"22","author":"Long","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2020.108233_bib98","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1756283X12450934","article-title":"Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron","volume":"5","author":"Lucak","year":"2012","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib99","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1517\/14656566.4.11.2089","article-title":"Alosetron and irritable bowel syndrome","volume":"4","author":"Mayer","year":"2003","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2020.108233_bib100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000026665","article-title":"(+\/-)3,4-methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies","volume":"42","author":"McCann","year":"2000","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib101","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00004714-199110000-00005","article-title":"Lasting neuropsychiatric sequelae of (+\/-)methylenedioxymethamphetamine (ecstasy) in recreational users","volume":"11","author":"McCann","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib102","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/0006-3223(92)90185-3","article-title":"MDMA (ecstasy) and panic disorder - induction by a single dose","volume":"32","author":"McCann","year":"1992","journal-title":"Biol. Psychiatr."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108233_bib103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/npp.1994.15","article-title":"Serotonin neurotoxicity after (+\/-)3,4-methylenedioxymethamphetamine (MDMA ecstasy) - a controlled-study in humans","author":"McCann","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib105","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0140-6736(98)04329-3","article-title":"Positron emission tomographic evidence of toxic effect of MDMA (\"Ecstasy\") on brain serotonin neurons in human beings","volume":"352","author":"McCann","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108233_bib106","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002130050967","article-title":"Cognitive performance in (+\/-) 3,4-methylenedioxymethamphetamine (MDMA, \"ecstasy\") users: a controlled study","volume":"143","author":"McCann","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib107","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(05)75652-X","article-title":"Positron emission tomography findings in heavy users of MDMA - Reply","volume":"353","author":"McCann","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108233_bib108","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpsyc.58.10.907","article-title":"Ecstasy\" and serotonin neurotoxicity - new findings raise more questions","volume":"58","author":"McCann","year":"2001","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/syn.20471","article-title":"Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users","volume":"62","author":"McCann","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2020.108233_bib110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00213-008-1218-4","article-title":"Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+\/-)3,4-methylenedioxymethamphetamine (\"ecstasy\") users: relationship to cognitive performance","volume":"200","author":"McCann","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib111","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1517\/14740338.5.2.313","article-title":"General - the rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome","volume":"5","author":"McLaughlin","year":"2006","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2020.108233_bib112","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","article-title":"Treatment of the neuroleptic-nonresponsive schizophrenic patient","volume":"18","author":"Meltzer","year":"1992","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2020.108233_bib113","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2003.09.010","article-title":"What's atypical about atypical antipsychotic drugs?","volume":"4","author":"Meltzer","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"issue":"64","key":"10.1016\/j.neuropharm.2020.108233_bib114","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.neuropharm.2020.108233_bib115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia - international suicide prevention trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib117","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/00002826-199518003-00003","article-title":"Suicide in schizophrenia: the effect of clozapine","volume":"18","author":"Meltzer","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib118","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors : their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib119","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1172\/JCI70678","article-title":"Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs","volume":"123","author":"Meltzer","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2020.108233_bib120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1569-7339(10)70074-6","article-title":"Distribution of 5-HT receptors in the central nervous system","volume":"21","author":"Mengod","year":"2010","journal-title":"Handbook of Behavioral Neurobiology of Serotonin"},{"key":"10.1016\/j.neuropharm.2020.108233_bib121","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1468-2982.1996.1601005.x","article-title":"Side effects of ergotamine","volume":"16","author":"Meyler","year":"1996","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2020.108233_bib122","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2165\/00003495-199141040-00006","article-title":"Ondansetron - therapeutic use as an antiemetic","volume":"41","author":"Milne","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2020.108233_bib123","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1749-6632.1990.tb16916.x","article-title":"Neurotoxicity of MDMA and related-compounds - anatomic studies","volume":"600","author":"Molliver","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2020.108233_bib124","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1751-2980.12045","article-title":"Retrospective analysis of disease association and outcome in histologically confirmed ischemic colitis","volume":"14","author":"Mosli","year":"2013","journal-title":"Journal of Digestive Diseases"},{"key":"10.1016\/j.neuropharm.2020.108233_bib125","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(11)60334-6","article-title":"Mediator scandal rocks French medical community","volume":"377","author":"Mullard","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108233_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)61106-X","article-title":"Mediator scandal engulfs French compensation body","volume":"381","author":"Mullard","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108233_bib127","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.lpm.2013.02.310","article-title":"About the settlement of litigations concerning the harm caused by benfluorex (Mediator (R))","volume":"42","author":"Nicot","year":"2013","journal-title":"Presse Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108233_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002047","article-title":"Illegal drugs laws: clearing a 50-year-old obstacle to research","volume":"13","author":"Nutt","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib129","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1517\/14656566.5.11.2369","article-title":"Review of tegaserod in the treatment of irritable bowel syndrome","volume":"5","author":"Patel","year":"2004","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2020.108233_bib130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.1995.13.4.1036","article-title":"Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis","volume":"13","author":"Perez","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib131","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1592\/phco.24.16.1649.50956","article-title":"Tegaserod-induced myocardial infarction: case report and hypothesis - an alternative viewpoint","volume":"24","author":"Pfannkuche","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2020.108233_bib133","first-page":"463","article-title":"Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study","volume":"18","author":"Rasmussen","year":"2009","journal-title":"J. Heart Valve Dis."},{"key":"10.1016\/j.neuropharm.2020.108233_bib134","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.300.5625.1504","article-title":"MDMA (\"ecstasy\") and neurotoxicity - Response","volume":"300","author":"Ricaurte","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108233_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-6147(03)00134-2","article-title":"Response to O'Shea and Colado: the MDMA neurotoxicity profile might provide clues to mechanisms","volume":"24","author":"Ricaurte","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108233_bib136","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0149-2918(03)80198-4","article-title":"Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review","volume":"25","author":"Rivkin","year":"2003","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108233_bib137","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fnhum.2014.00204","article-title":"The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers","volume":"8","author":"Roseman","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108233_bib138","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib139","first-page":"61","article-title":"Designer drugs: how dangerous are they?","author":"Reneman","year":"2003","journal-title":"JNT (J. Neural Transm.) Suppl."},{"key":"10.1016\/j.neuropharm.2020.108233_bib141","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0140-6736(01)06888-X","article-title":"Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons","volume":"358","author":"Reneman","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108233_bib142","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hup.347","article-title":"Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach","volume":"16","author":"Reneman","year":"2001","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.neuropharm.2020.108233_bib143","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archpsyc.58.10.901","article-title":"Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or \"ecstasy\") - preliminary findings","volume":"58","author":"Reneman","year":"2001","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib144","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/syn.10130","article-title":"Validity of I-123 beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity","volume":"46","author":"Reneman","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2020.108233_bib145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00213-001-0930-0","article-title":"Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a I-123 beta-CIT SPECT study - preliminary report","volume":"159","author":"Reneman","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib146","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1056\/NEJMp068265","article-title":"Dopamine agonists and valvular heart disease - Reply","volume":"356","author":"Roth","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.108233_bib147","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Focus on research - drug and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.108233_bib148","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.neuropharm.2011.01.012","article-title":"Irving Page Lecture: 5-HT2A serotonin receptor biology: interacting proteins, kinases and paradoxical regulation","volume":"61","author":"Roth","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib149","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0022-3565(24)36476-6","article-title":"High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine(2A) receptors: evidence in favor of a modified ternary complex model","volume":"280","author":"Roth","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108233_bib152","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/107385849900500414","article-title":"Activation is hallucinogenic and antagonism is therapeutic: role of 5-HT2A receptors in atypical antipsychotic drug actions","volume":"5","author":"Roth","year":"1999","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2020.108233_bib156","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2020.108233_bib157","first-page":"211","article-title":"Recent advances in gastrointestinal prokinetic agents","volume":"vol. 41","author":"Sandham","year":"2006"},{"key":"10.1016\/j.neuropharm.2020.108233_bib158","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2982.1996.tb00270.x","article-title":"5-hydroxytryptamine and functional bowel disorders","volume":"8","author":"Sanger","year":"1996","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.neuropharm.2020.108233_bib159","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tips.2008.06.008","article-title":"5-hydroxytryptamine and the gastrointestinal tract: where next?","volume":"29","author":"Sanger","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108233_bib160","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2982.2009.01425.x","article-title":"Translating 5-HT4 receptor pharmacology","volume":"21","author":"Sanger","year":"2009","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.neuropharm.2020.108233_bib162","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.2042-7158.1994.tb03879.x","article-title":"Constipation evoked by 5-HT3-receptor antagonism - evidence for heterogeneous efficacy among different antagonists in Guinea-pigs","volume":"46","author":"Sanger","year":"1994","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib163","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1183\/09031936.00188611","article-title":"Pulmonary hypertension associated with benfluorex exposure","volume":"40","author":"Savale","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.neuropharm.2020.108233_bib164","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00169219","article-title":"How selective is GR-43175 - interactions with functional 5-ht1a, 5-ht1b, 5-ht1c and 5-ht1d receptors","volume":"340","author":"Schoeffter","year":"1989","journal-title":"N. Schmied. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(89)90692-4","article-title":"Is the sumatriptan (GR 43175)-induced endothelium-dependent relaxation of pig coronary-arteries mediated by 5-HT1D receptors","volume":"166","author":"Schoeffter","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00138","article-title":"A review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted psychotherapy","volume":"10","author":"Sessa","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib167","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1124\/mol.104.009266","article-title":"Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor","volume":"68","author":"Setola","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib168","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-methylenedioxymethamphetamine (MDMA, \"Ecstasy\") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib169","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/apt.12571","article-title":"Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation","volume":"39","author":"Shin","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108233_bib170","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1161\/01.CIR.100.21.2161","article-title":"Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine","volume":"100","author":"Shively","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2020.108233_bib171","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/mds.21639","article-title":"Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine Agonists","volume":"22","author":"Simonis","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108233_bib172","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroimage.2019.04.009","article-title":"Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects","volume":"196","author":"Smigielski","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2020.108233_bib173","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.coph.2008.07.003","article-title":"Serotonergic agents and the irritable bowel syndrome: what goes wrong?","volume":"8","author":"Spiller","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib174","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coph.2011.02.005","article-title":"Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome","volume":"11","author":"Spiller","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108233_bib175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/bchm2.1938.251.1-6.155","article-title":"Partial synthesis of ergobasine, a natural ergot alkaloid as well as optical antipodes. 3. Announcement on ergot alkaloids","volume":"251","author":"Stoll","year":"1938","journal-title":"Hoppe-Seylers Zeitschrift Fur Physiologische Chemie"},{"key":"10.1016\/j.neuropharm.2020.108233_bib176","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/hlca.19430260522","article-title":"Alkaloid of the ergotoxin group: ergocristin, ergokryptin and ergocornin. (7. Announcement on ergot alkaloids.)","volume":"26","author":"Stoll","year":"1943","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.neuropharm.2020.108233_bib177","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hlca.19430260633","article-title":"Dihydro derivative of natural levorotary ergot alkaloids (9(th) Announcement on ergot alkaloids)","volume":"26","author":"Stoll","year":"1943","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.neuropharm.2020.108233_bib178","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/pds.3642","article-title":"Adverse effects of benfluorex on heart valves and pulmonary circulation","volume":"23","author":"Szymanski","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.neuropharm.2020.108233_bib179","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","article-title":"Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders","volume":"35","author":"Tack","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108233_bib180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/123.1.9","article-title":"Ergotamine in the acute treatment of migraine - a review and European consensus","volume":"123","author":"Tfelt-Hansen","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108233_bib181","author":"The New York times"},{"key":"10.1016\/j.neuropharm.2020.108233_bib182","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2146\/news130057","article-title":"FDA's advisers recommend updating alosetron's REMS","volume":"70","author":"Thompson","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.neuropharm.2020.108233_bib183","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1756283X13491798","article-title":"A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program","volume":"6","author":"Tong","year":"2013","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib185","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.lpm.2011.09.001","article-title":"Benfluorex and valvular heart disease","volume":"40","author":"Tribouilloy","year":"2011","journal-title":"Presse Med."},{"key":"10.1016\/j.neuropharm.2020.108233_bib186","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1093\/eurheartj\/eht266","article-title":"Frequency of drug-induced valvular heart disease in patients previously exposed to benfluorex: a multicentre prospective study","volume":"34","author":"Tribouilloy","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.neuropharm.2020.108233_bib187","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ejechocard\/jeq027","article-title":"Restrictive organic mitral regurgitation associated with benfluorex therapy","volume":"11","author":"Tribouilloy","year":"2010","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.neuropharm.2020.108233_bib188","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1161\/CIRCULATIONAHA.112.111260","article-title":"Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus A multicenter study","volume":"126","author":"Tribouilloy","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2020.108233_bib189","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108233_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(11)60861-1","article-title":"Mediator: who's to blame?","volume":"377","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108233_bib191","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1126\/science.1232808","article-title":"Structural features for functional selectivity at serotonin receptors","volume":"340","author":"Wacker","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108233_bib192","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal structure of an LSD-bound human serotonin receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2020.108233_bib193","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1126\/science.1232807","article-title":"Structural basis for molecular recognition at serotonin receptors","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108233_bib194","article-title":"Tegaserod has no potential for vasoconstriction or impairment of vasodilatation in isolated human and non-human primate mesenteric arteries","volume":"130","author":"Weber","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2020.108233_bib196","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-199448050-00008","article-title":"Granisetron - an update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy","volume":"48","author":"Yarker","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2020.108233_bib197","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N. Engl. J. Med."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820303014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820303014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:05:16Z","timestamp":1758438316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820303014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":182,"alternative-id":["S0028390820303014"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108233","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the 5-HT system: Potential side effects","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108233"}}